Title	Effects of calmodulin and protein kinase C modulators on transient Ca2+ increase and capacitative Ca2+ entry in human platelets: relevant to pathophysiology of bipolar disorder
Author(s)	Akimoto, Tatsuyuki; Kusumi, Ichiro; Suzuki, Katsuji; Koyama, Tsukasa
Citation	Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31(1), 136-141 https://doi.org/10.1016/j.pnpbp.2006.08.008
Issue Date	2007-01-30
Doc URL	http://hdl.handle.net/2115/33034
Туре	article (author version)
File Information	kusumi.pdf



Effects of calmodulin and protein kinase C modulators on transient Ca²⁺ increase and

capacitative Ca²⁺ entry in human platelets: Relevant to pathophysiology of bipolar disorder

Tatsuyuki Akimoto^{1,2}, Ichiro Kusumi^{1,*}, Katsuji Suzuki¹, and Tsukasa Koyama¹

1 Department of Psychiatry, Hokkaido University Graduate School of Medicine

North 15 - West 7, Kita-ku, Sapporo 060-8638, Japan

2 Department of Psychiatry, Kushiro City General Hospital

1-12 Shunkodai, Kushiro 085-0822, Japan

Corresponding author: Ichiro Kusumi, M.D., Ph.D.

Department of Psychiatry, Hokkaido University Graduate School of Medicine

North 15 - West 7, Kita-ku, Sapporo 060-8638, Japan

TEL: 81+11-706-5160, FAX: 81+11-706-5081

E-mail: ikusumi@med.hokudai.ac.jp

Abstract:

Disturbed intracellular calcium (Ca²⁺) homeostasis has been implicated in bipolar disorder, which mechanisms may be involved in the dysregulation of protein kinase C (PKC) and calmodulin systems. In this study, we investigated a transient intracellular Ca2+ increase induced by thapsigargin, a inhibitor of sarco/endoplasmic reticulum Ca2+-ATPase pump (SERCA), and a capacitative Ca²⁺ entry followed by addition of extracellular Ca²⁺, in the presence or absence of PKC/calmodulin modulators in the platelets of healthy subjects in order to elucidate the role of SERCA in Ca²⁺ homeostasis and to assess how both PKC and calmodulin systems regulate the two Ca²⁺ responses. Moreover, we also examined the thapsigargin-elicited transient Ca²⁺ increase and capacitative Ca²⁺ entry in patients with mood disorders. PKC and calmodulin systems have opposite regulatory effects on the transient Ca2+ increase and capacitative Ca2+ entry in the platelets of normal subjects. The inhibitory effect of PKC activation on capacitative Ca²⁺ entry is significantly increased and the stimulatory effect of PKC inhibition is significantly decreased in bipolar disorder compared to major depressive disorder and normal controls. These results suggest the possibility that increased PKC activity may activate the inhibitory effect of capacitative Ca²⁺ entry in bipolar disorder. However, this is a preliminary study using a small sample, thus further studies are needed to examine the PKC and calmodulin modulators on the capacitative Ca²⁺ entry in a larger sample.

Key words: Bipolar disorder; Calcium; Calmodulin; Platelet; Protein kinase C; Thapsigargin **Abbreviations**: Ca²⁺; intracellular calcium, ER; endoplasmic reticulum, 5-HT; serotonin, MLCK; myosin light chain kinase, PKC; protein kinase C, PRP; platelet rich plasma, SERCA;

sarco/endoplasmic reticulum Ca²⁺-ATPase pump, TG; thapsigargin

Introductions

It has been suggested that intracellular calcium (Ca²⁺) mobilization is dysregulated in the platelets of bipolar disorders. We have reported that serotonin (5-HT)- or thrombin-induced intraplatelet Ca²⁺ mobilization is enhanced in unmedicated patients with bipolar disorder (Kusumi et al. 1992; 1994; Suzuki et al. 2001). Other researchers have indicated similar findings (Dubovsky et al. 1991; Okamoto et al. 1995). Moreover, the 5-HT-stimulated Ca²⁺ response is significantly attenuated in the presence of staurosporine, a protein kinase C (PKC) inhibitor, in normal controls and major depressive disorder, whereas the inhibitory effect of staurosporine is not observed in bipolar disorder (Suzuki et al. 2003). This finding suggests increased PKC activity in bipolar disorder as shown by other investigators (Friedman et al. 1993; Wang and Friedman 1996; Pandey et al. 1998; Wang et al. 1999). Meanwhile, in the presence of ML-9, a myosin light chain kinase (MLCK) inhibitor, both 5-HT- and thrombin-induced Ca²⁺ response are enhanced in the platelets of normal subjects (Suzuki et al. 2004). This result suggests that the enhanced Ca²⁺ response observed in bipolar disorder may be relevant to decreased function of MLCK, a Ca²⁺/calmodulin-dependent enzyme. These findings indicate that the dysregulation of Ca²⁺ mobilization in bipolar disorder may be closely related to PKC and calmodulin systems.

It is well established that depletion of intracellular stores of Ca²⁺ can activate Ca²⁺ influx across the plasma membrane, a process known as 'capacitative Ca²⁺ entry' (Putney 1986). It can be switched on by variety of stimuli such as Ca²⁺ mobilizing agonists, inositol 1,4,5-triphosphate, Ca²⁺ ionophore ionomycin or inhibitor of sarco/endoplasmic reticulum Ca²⁺-ATPase pump (SERCA) thapsigargin (Berridge 1995). Pathogenic mutations of ATP2A2 gene at chromosome

12q which encodes SERCA has recently been identified in Darier's disease, a dominant skin disorder, which often comorbid with bipolar disorders (Craddock et al. 1994). Findings from a recent linkage study suggest that this chromosomal region may contain a susceptibility gene for bipolar disorders (Dawson et al. 1995). Moreover, DNA microarray analysis of lymphoblastoid cells derived from pairs of twins discordant with respect to bipolar disorder, suggested that a polymorphism of XBP1, a pivotal gene in the endoplasmic reticulum (ER) stress response elicited by thapsigargin, might contribute to the genetic risk factor for bipolar disorder (Kakiuchi et al. 2003).

In this study, we investigated the effects of thapsigargin on intracellular Ca²⁺ concentration in the presence or absence of PKC/calmodulin modulators in the platelets of healthy subjects in order to elucidate the role of SERCA in Ca²⁺ homeostasis and to assess how both PKC and calmodulin systems regulate the thapsigargin-induced Ca²⁺ mobilization. Moreover, we also preliminarily examined the thapsigargin-elicited transient Ca²⁺ increase and capacitative Ca²⁺ entry in patients with mood disorder.

Methods

Subjects

For basic study, subjects were 6 healthy male volunteers (29-43 years old), free of psychiatric and physical illness. For patient study, subjects were 7 patients with bipolar disorder (euthymic or depressive), 10 patients with major depressive disorder (all depressive) and 17 sex- and age-matched control diagnosed by two psychiatrists using DSM-IV criteria. The patients were

drug-naïve except 3 bipolar patients treated with lithium (1 case), levothyroxine (2 cases), cabergoline (2 cases), risperidone (1 case), olanzapine (1 case) and quetiapine (1 case). Written informed consent was obtained from all participants prior to blood sampling, which was approved by the Institutional Review Board in Hokkaido University Graduate School of Medicine. For at least 4 weeks before blood sampling, all subjects had not received any calcium channel blocking medication, acetylsalicylic acid or non-steroidal anti-inflammatory drugs.

Measurement of intracellular Ca concentration

The isolation of platelets and the measurement of intracellular Ca²⁺ concentration were performed as described previously (Kusumi et al. 1991a; 1991b). Briefly, platelet rich plasma (PRP) was prepared by centrifugation at 200 x g for 10 min at room temperature. After incubation with 4 μM fura-2/acetoxymethyl ester for 15 min, platelets were isolated from the PRP by further centrifugation at 600 x g for 15 min. The platelet pellet was suspended in Krebs-Ringer HEPES buffer (145 mM NaCl, 5 mM KCl, 1 mM MgSO₄, 0.5 mM Na₂HPO₄, 6 mM glucose, 10mM HEPES, pH 7.4). Fluorescence was measured on a Hitachi F-2000 fluorometer with excitation at 340 and 380 nm, and with emission at 510 nm using a Ca²⁺-dye dissociation constant of 224 nM. Intracellular Ca²⁺ concentrations were calculated from the ratio of fluorescence intensities at two excitation wavelengths in the platelet samples according to the method of Grynkiewicz et al. (1985). Ca²⁺ increase represents that initial peak minus resting level.

Basic study I; Measurement of transient Ca2+ increase and capacitative Ca2+ entry in the

platelets of normal controls

In <u>nominal</u> Ca^{2+} -free buffer, we measured a transient Ca^{2+} increase by adding various concentrations (1nM-10 μ M) of thapsigargin to the platelet suspension. After intracellular Ca^{2+} concentration reached a steady state, we measured a capacitative Ca^{2+} entry by restoring extracellular Ca^{2+} (1mM $CaCl_2$).

<u>Basic study II</u>; Effects of PKC and calmodulin modulators on transient Ca^{2+} increase and capacitative Ca^{2+} entry in the platelets of normal control

Either W-7 (1-100 μ M), a calmodulin antagonist, PMA (0.1-10 nM), a PKC activator or bisindolylmaleimide II (10-1000 nM), a PKC inhibitor was pre-incubated at 37 C° for 4 min prior to thapsigargin stimulation. The effects of PKC and calmodulin modulators on a transient Ca²⁺ increase and capacitative Ca²⁺ entry were assessed by the same method as in the basic I study using 30nM thapsigargin and 1mM CaCl₂.

Patient Study

In the absence or presence of the PKC and calmodulin modulators mentioned above, we compared the transient Ca²⁺ increase and the capacitative Ca²⁺ entry among patients with bipolar disorder and major depressive disorder, and normal controls.

Statistical analysis

Values were expressed as the mean±SEM. Statistical evaluation was performed using

repeated-measures analysis of variance followed by a Dunnett's test. Differences were considered statistically significant at P < 0.05.

Results

For basic study, in nominal Ca²⁺-free buffer, thapsigargin (1nM-10µM) induced a transient Ca²⁺ increase in a concentration-dependent manner in the platelets of healthy subjects. Its EC₅₀ is 65 nM (Fig 1a). In the presence of extracellular $Ca^{2+}(1mM\ CaCl_2)$, thapsigargin $(1\mu M)$ induced a long lasting increase in intracellular Ca²⁺ concentration (Fig 1b). Thapsigargin (10-100 nM) enhanced dose-dependently the Ca²⁺ response to the addition of 1mM CaCl₂ (Fig 1c). In the presence of 30 µM and more concentrations of W-7, both the transient Ca²⁺ increase induced by 30 nM thapsigargin (Fig 2a) and the capacitative Ca²⁺ entry by the addition of 1 mM CaCl₂ (Fig 2b) were significantly attenuated in normal controls. Pre-treatments with 3-10 nM PMA significantly inhibited the transient Ca²⁺ increase (Fig 3a) and 1-10 nM PMA also significantly reduced the capacitative Ca²⁺ entry (Fig 3b). On the other hand, bisindolylmaleimide II significantly enhanced both the transient Ca^{2+} increase at 100 nM $- 1 \mu M$ (Fig 4a) and the capacitative Ca²⁺ entry at 500 nM - 1 µM (Fig 4b). Each PKC or calmodulin modulator was effective within the range of concentrations that have a specific action in intact platelets (Kaibuchi et al. 1982; Nishikawa et al. 1980; Toullec et al. 1991). For capacitative Ca²⁺ entry, similar results were obtained by the addition of each PKC or calmodulin modulator after thapsigargin stimulation (data not shown).

For patient study, there was no significant difference in either transient Ca2+ increase or

capacitative Ca2+ entry among patients with bipolar disorder and major depressive disorder, and normal controls (Fig 5a and 5b). Next, we examined the effects of PKC and calmodulin modulators on the two Ca²⁺ responses among the three groups by comparing percentage of Ca²⁺ increase which calculates as follows; Ca²⁺ increase with pre-treatment / Ca²⁺ increase without pre-treatment x100 (%). No significant difference in the effect of PKC or calmodulin modulators on the transient Ca²⁺ increase was found between patients with bipolar disorder and major depressive disorder, and normal controls (Fig 6a). Although there was no significant difference in the effect of W-7 (49.0% for bipolar disorder, 57.3% for major depressive disorder, 51.1% for normal control), capacitative Ca²⁺ entry was significantly inhibited by PMA in bipolar disorder compared to normal controls (Fig 6b; 24.6% for bipolar disorder, 53.1% for major depressive disorder, 60.6% for normal control, p < 0.05). The enhancement of capacitative Ca^{2+} entry by bisindolylmaleimide II was significantly lower in bipolar disorder than in major depressive disorder and normal control (Fig 6b; 106.0% for bipolar disorder, 127.8% for major depressive disorder, 137.6% for normal control, p < 0.05). For bipolar patients, there is no significant difference in capacitative Ca2+ entry pretreated with PMA or bisindolylmaleimide II between medicated and non-medicated groups (data not shown) although it is a preliminary analysis based on a small sample.

Discussion

The present results suggested that PKC activator negatively, and PKC inhibitor positively regulated the Ca²⁺ leakage from internal Ca²⁺ store that follows the inhibition of the SERCA, and

the capacitative Ca^{2+} entry induced by the depletion of internal Ca^{2+} stores in human platelets. In contrast with PKC inhibitor, a calmodulin antagonist caused inhibitory effects on both the transient Ca^{2+} increase and capacitative Ca^{2+} entry. Taken together, these results may indicate the possibility that PKC and calmodulin systems have opposite regulatory effects on the two Ca^{2+} responses.

Recently several reports indicate that capacitative Ca²⁺ entry has been found in CNS (Grudt et al. 1996; Lo et al. 2002) and may have a role in synaptic plasticity (Baba et al. 2003). In platelets, it is known that PKC activates Ca²⁺ entry into ER through increasing the Vmax of SERCA (Tao et al. 1992). Therefore, the present results that Ca²⁺ efflux from ER decreases by PKC activation and increases by PKC inhibition, may possibly be due to this direct effect of PKC on SERCA. For calmodulin systems, similar finding was reported on the effect of calmodulin inhibitor upon capacitative Ca²⁺ entry in cultured human mesangial cells (Mene et al. 1996). However, to our knowledge, this is the first report to examine the effect of calmodulin modulator on capacitative Ca²⁺ entry in platelets. It is possible that SERCA itself may be directly regulated by calmodulin in the same way as PKC system.

There have been a few reports to examine whether SERCA-related Ca^{2+} mobilization have some role in the pathphysiology of bipolar disorder. Hough et al.(1999) reported that the platelets / lymphocytes of bipolar patients responded to thapsigargin with greater intracellular Ca^{2+} increases than did control subjects. However, the thapsigargin-induced Ca^{2+} influx was measured in the Ca^{2+} -containing buffer, thus it is uncertain for the transient Ca^{2+} increase and capacitative Ca^{2+} entry in their study. Another difference in methodology is the concentration of

thapsigargin (30 nM in our study vs. 1 μ M in Hough's study). It is shown that there are two subfamilies of SERCA, SERCA2b and SERCA3 in platelets (Kovacs et al. 2001). SERCA2b is sensitive to low concentration (10 nM) of thapsigargin, while SERCA3 is sensitive to higher concentration (100-200 nM) (Cavallini et al. 1995). Kato et al.(2003) showed that 10 μ M thapsigargin-induced cytosolic Ca²⁺ response was significantly higher in the transformed lymphoblastoid cells from patients with bipolar disorder only in the presence of extracellular Ca²⁺.

The present preliminary patient study shows that the inhibitory effect of PKC activation on capacitative Ca²⁺ entry is significantly increased and the stimulatory effect of PKC inhibition is significantly decreased in patients with bipolar disorder compared to patients with major depressive disorder and normal controls. However, there is no significant difference in effect of calmodulin inhibitor on the capacitative Ca²⁺ entry, or effect of PKC or calmodulin modulators on the transient Ca²⁺ increase among the three groups. These results suggest the possibility that increased PKC activity may activate the inhibitory effect of capacitative Ca²⁺ entry in bipolar disorder. Actually, there have been several reports showing that the PKC activity is enhanced in the postmortem brain and platelets of patients with bipolar disorder (Friedman et al. 1993; Wang et al. 1996; Wang et al. 1999).

As mentioned in the introduction, Kakiuchi et al.(2003) reported that a polymorphism in the promoter region of XBP1, a pivotal gene in the ER stress response elicited by thapsigargin etc., increased the risk of bipolar disorder. Although there have been no report showing a direct connection between the XBP1 polymorphism and SERCA function or clear evidence of altered SERCA function in bipolar disorder, the present study suggests the possibility that decreased

basis of capacitative Ca²⁺ entry remains elusive, but transient receptor potential channel families have been put forward as possible candidates. Especially, transient receptor potential Ca²⁺ permeable channel melastatin type 2 (TRPM2) is one of candidates in regards to the etiology of bipolar disorder (McQuillin et al. 2006; Xu et al. 2006). It may be worth examining the relationship between these SNPs and capacitative Ca²⁺ entry in bipolar disorder.

In conclusion, PKC and calmodulin systems have opposite regulatory effects on the transient Ca²⁺ increase and capacitative Ca²⁺ entry in the platelets of normal subjects. The inhibitory effect of PKC activation on capacitative Ca²⁺ entry is significantly increased and the stimulatory effect of PKC inhibition is significantly decreased in bipolar disorder compared to major depressive disorder and normal controls. These results suggest the possibility that the increased activity of PKC may activate the inhibitory effect of capacitative Ca²⁺ entry in bipolar disorder. However, this study is preliminary using a small sample, thus further studies are needed to examine the PKC and calmodulin modulators on the capacitative Ca²⁺ entry in a larger sample.

Acknowledgments

This work was partly supported by grants-in-aid for Soul and diseases-of-the-nervous-system research (T. Koyama) from Japanese Ministry of Health, Labor and Welfare, and for Scientific Research No. 17591192 (I. Kusumi) from Japanese Ministry of Education, Culture, Sports, Science and Technology.

References

Baba A, Yasui T, Fujisawa S, Yamada RX, Yamada MK, Nishiyama N, et al (2003). Activity-evoked capacitative Ca²⁺ entry: implications in synaptic plasticity. J Neurosci; 23: 7737-7741

Berridge MJ (1995). Capacitative calcium entry. Biochem J; 312: 1-11

Calvallini L, Coassin M, Alexandre A (1995). Two classes of agonist-sensitive Ca²⁺ stores in platelets, as identified by their differential sensitivity to 2,5-di-(tert-butyl)-1,4-benzohydroquinone and thapsigargin. Biochem J; 310: 449-452

Craddock N, Owen M, Burge S (1994). Familial cosegregation of major affective disorder and Darier's disease (keratosis follicularis). Br J Psychiatry; 164: 355-358

Dawson E, Parfitt E, Roberts Q (1995). Linkage studies of bipolar disorder in the region of the Darier's disease gene on chromosome 12q23-24.1. Am J Med Genet; 60: 94-102

Dubovsky SL, Lee C, Christiano J, Murphy J (1991). Elevated platelet intracellular calcium concentration in bipolar depression. Biol Psychiatry; 29: 441-450

Friedman E, Wang HY, Levinson D, Connell TA, Sing H (1993). Altered platelet protein kinase C

activity in bipolar affective disorder, manic episode. Biol Psychiatry; 33: 520-525

Grudt TJ, Usowicz MM, Henderson G (1996). Ca²⁺ entry following store depletion in SH-SY5Y neuroblastoma cells. Mol Brain Res; 36: 93-100

Grynkiewicz G, Poenie M, Tsien RY (1985). A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. J Biol Chem; 260: 3440-3450

Hough C, Lu S-J, Davis CL, Chuang D-M, Post RM (1999). Elevated basal and thapsigargin-stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay. Biol Psychiatry; 46: 247-255

Kaibuchi K, Sano K, Hoshijima M, Takai Y, Nishizuka Y (1982). Phosphatidylinositol turnover in platelet activation; calcium mobilization and protein phosphorylation. Cell Calcium; 3: 323-335

Kakiuchi C, Iwamoto K, Ishiwata M, Bundo M, Kasahara T, Kusumi I, et al (2003). Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. Nat Genet; 35: 171-175

Kato T, Ishiwata M, Mori K, Washizuka S, Tajima O, Akiyama T, et al (2003). Mechanisms of altered Ca2+ signalling in transformed lymphoblastoid cells from patients with bipolar disorder. Int J Neuropsychopharmacol; 6: 379-389

Kovacs T, Felfoeldi F, Papp B, Paszty K, Bredoux R, Enyedi A, et al (2001). All three splice variants of the human sarco/endoplasmic reticulum Ca²⁺-ATPase 3 gene are translated to proteins: a study of their co-expression in platelets and lymphoid cells. Biochem J; 358: 559-568

Kusumi I, Koyama T, Yamashita I (1991a. Effect of various factors on serotonin-induced Ca²⁺ response in human platelets. Life Sci; 48: 2405-2412

Kusumi I, Koyama T, Yamashita I (1991b). Serotonin-stimulated Ca²⁺ response is increased in the blood platelets of depressed patients. Biol Psychiatry; 30: 310-312

Kusumi I, Koyama T, Yamashita I (1992). Thrombin-induced platelet calcium mobilization in enhanced in bipolar disorder. Biol Psychiatry; 32: 731-734

Kusumi I, Koyama T, Yamashita I (1994). Serotonin-induced platelet intracellular calcium mobilization in depressed patients. Psychopharmacology; 113: 322-327

Lo KJ, Luk HN, Chin TY, Chueh SH (2002). Store depletion-induced calcium influx in rat cerebellar astrocytes. Br J Pharmacol; 135: 1383-1392

McQuillin A, Bass NJ, Kalsi G, Lawrence J, Puri V, Choudhury K, et al (2006). Fine mapping of a

susceptibility locus for bipolar and genetically related unipolar affective disorders, to a region containing the C21ORF29 and TRPM2 genes on chromosome 21q22.3. Mol Psychiatry; 11: 134-142

Mene P, Pugliese F, Cinotti GA (1996). Regulation of capacitative calcium influx in cultured human mesangial cells: roles of protein kinase C and calmodulin. J Am Soc Nephrol; 7: 983-990

Nishikawa M, Tanaka T, Hidaka H (1980).Ca²⁺-calmodulin-dependent phosphorylation and platelet secretion. Nature; 287: 863-865

Okamoto Y, Kagaya A, Shinno H (1995). Serotonin-induced platelet calcium mobilization is enhanced in mania. Life Sci; 56: 327-332

Pandey GN, Dwivedi Y, Kumari R, Janicak PG (1998). Protein kinase C in platelets of depressed patients. Biol Psychiatry; 44: 909-911

Putney Jr JW (1986). A model for receptor-regulated calcium entry. Cell Calcium; 7: 1-12

Suzuki K, Kusumi I, Sasaki Y, Koyama T (2001). Serotonin-induced platelet intracellular calcium mobilization in various psychiatric disorders: Is it specific to bipolar disorder? J Affect Disord; 64: 291-296

Suzuki K, Kusumi I, Akimoto T, Sasaki Y, Koyama T (2003). Altered 5-HT-induced calcium response in the presence of staurosporine in blood platelets from bipolar disorder patients. Neuropsychopharmacology; 28: 1210-1214

Suzuki K, Kusumi I, Akimoto T, Sasaki Y, Koyama T (2004). Effects of lithium and valproate on agonist-induced platelet intracellular calcium mobilization: relevance to myosin light chain kinase. Prog Neuro-Psychopharmacol & Biol Psychiatry; 28: 67-72

Tao J, Johansson JS, Haynes DH (1992). Protein kinase C stimulates dense tubular Ca^{2+} uptake in the intact human platelet by increasing the V_m of the Ca^{2+} -ATPase pump: stimulation by phorbol ester, inhibition by calphostin C. Biochim Biophys Acta; 1107: 213-222

Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, et al (1991). The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem; 266: 15771-15781

Wang HY, Friedman E (1996). Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry; 40: 568-575

Wang HY, Markowitz P, Levinson D, Undie AS, Friedman E (1999). Increased

membrane-associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients. J Psychiat Res; 33: 171-179

Xu C, Macciardi F, Li PP, Yoon IS, Cooke RG, Hughes B, et al (2006). Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder.

Am J Med Genet;141: 36-43

Figure legends

Fig 1. Effect of Ca²⁺-ATPase inhibitor thapsigargin on platelet intracellular Ca²⁺ mobilization.

- (a) In normal Ca^{2+} -free buffer, thapsigargin (TG) stimulated a transient increase in intracellular Ca^{2+} concentration by releasing from endoplasmic reticulum Ca^{2+} stores. Columns are the mean±SEM. (N= 6).
- (b) In the presence of extracellular $Ca^{2+}(1mM\ CaCl_2)$, $TG\ (1\mu M)$ stimulated a lasting increase in intracellular Ca^{2+} concentration. Each point is the mean±SEM. (N=4).
- (c) After a transient Ca^{2+} increase stimulated by TG in normal Ca^{2+} -free buffer, $CaCl_2(1mM)$ was added to the buffer, which induced a capacitative Ca^{2+} entry. Columns are the mean±SEM. (N=5.)

Fig 2. Effect of W-7 on (a) transient Ca²⁺ increase and (b) capacitative Ca²⁺ entry

W-7 was added 4 min prior to 30 nM thapsigargin stimulation. One factor repeated ANOVA was performed to analyze the each effect.

** p< 0.01 compared with control (C: without W-7); by Dunnett's test (N=4).

Fig 3. Effect of PMA on (a) transient Ca²⁺ increase and (b) capacitative Ca²⁺ entry

PMA was added 4 min prior to 30 nM thapsigargin stimulation. One factor repeated ANOVA was performed to analyze the each effect.

* p< 0.05, ** p< 0.01 compared with control (C: without PMA); by Dunnett's test (N=4).

Fig 4. Effect of bisindolylmaleimide II (BIS) on (a) transient Ca²⁺ increase and (b) capacitative Ca²⁺ entry

BIS was added 4 min prior to 30 nM thapsigargin stimulation. One factor repeated ANOVA was performed to analyze the each effect.


* p< 0.05, compared with control (C: without BIS) ; by Dunnett's test (N=6).

Fig 5. (a) Transient Ca²⁺ increase and (b) capacitative Ca²⁺ entry in patients with bipolar disorder and major depressive disorder, and control subjects

Fig 6. Effects of W-7, PMA or bisindolylmaleimide II (BIS) on (a) transient Ca²⁺ increase and (b) capacitative Ca²⁺ entry in patients with bipolar disorder and major depressive disorder, and normal controls.

Data are shown by percent of Ca^{2+} increase which calculates as follows; Ca^{2+} increase with pre-treatment / Ca^{2+} increase without pre-treatment x100 (%). TG: thapsigargin

^{*} p< 0.05, compared with control subjects; by Dunnett's test.






Fig. 1







Fig. 2







(b)

